Aldosterone & Sodium Regulation in Postural Tachycardia Syndrome - Screening
Primary Purpose
Postural Tachycardia Syndrome
Status
Active
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Autonomic Function Testing
Posture Study
Measurement of Total Blood Volume
Exercise Capacity Test
Sponsored by
About this trial
This is an interventional screening trial for Postural Tachycardia Syndrome focused on measuring Postural tachycardia syndrome, orthostatic intolerance, orthostatic tachycardia, POTS
Eligibility Criteria
Inclusion Criteria:
- Age between 18-50 years old
- Patients with suspected POTS and healthy volunteers
- Sedentary healthy subjects of similar age and gender than patients will also be recruited.
- Only female participants are eligible.
- Able and willing to provide informed consent
Exclusion Criteria:
- Smokers
- Overt cause for postural tachycardia, i.e., acute dehydration
- Significant cardiovascular, pulmonary, hepatic, or hematological disease by history or prior testing
- Highly trained athletes
- Subjects with somatization or severe anxiety symptoms will be excluded
- Pregnant (positive pregnancy test) or breastfeeding
- Hypertension defined as supine resting BP>145/95 mmHg off medications or needing antihypertensive medication
- Other factors which in the investigator's opinion would prevent the participant from completing the protocol, including poor compliance during previous studies or an unpredictable schedule
- Unable to give informed consent
Sites / Locations
- Vanderbilt University Medical Center
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
All participants
Arm Description
All participants will be administered all procedures as described previously. Interventions: Autonomic Function Testing, Posture Study ,Measurement of Total Blood Volume ,Exercise Capacity Test
Outcomes
Primary Outcome Measures
blood volume deviation (%) from individual predicted volumes
Compare blood volume deviations using the 131-I-Albumin method. Deviations will be reported as a percentage deviation from an individual's predicted value. These values will be compared between POTS patients and healthy control groups.
Secondary Outcome Measures
Full Information
NCT ID
NCT01783288
First Posted
January 25, 2013
Last Updated
November 22, 2022
Sponsor
Vanderbilt University
Collaborators
National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI)
1. Study Identification
Unique Protocol Identification Number
NCT01783288
Brief Title
Aldosterone & Sodium Regulation in Postural Tachycardia Syndrome - Screening
Official Title
Aldosterone and Sodium Regulation in Postural Tachycardia Syndrome - Screening Protocol
Study Type
Interventional
2. Study Status
Record Verification Date
November 2022
Overall Recruitment Status
Active, not recruiting
Study Start Date
February 2013 (undefined)
Primary Completion Date
December 2023 (Anticipated)
Study Completion Date
December 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Vanderbilt University
Collaborators
National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI)
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of the study is to determine whether patients meet criteria for Postural Tachycardia Syndrome (or not) and have reduced blood volume (or not). Both of these are important screening elements to Aim 3 of a National Institutes of Health Grant. The purposes of Aim 3 are to determine 1. whether a high dietary sodium level appropriately expands plasma volume in Postural Orthostatic Tachycardia, 2. whether plasma renin activity and aldosterone are modified appropriately by changes in dietary sodium in Postural Tachycardia Syndrome and 3. whether patients with Postural Tachycardia Syndrome have improvements in their orthostatic tachycardia and symptoms as a result of a high dietary sodium level.
Detailed Description
The protocol consists of a screening visit and evaluation of their autonomic nervous system status. The following activities are part of this study. Subjects may stay for 2 nights and 3 study days.
Day 0 Participants will be admitted to the Clinical Research Center, their medical history, physical exam, routine lab work (hemoglobin/hematocrit & CMP) and a serum pregnancy test will be done during that first day. They will also be asked to fill out a health questionnaire. Later that day they will be evaluated to determine the extent of fatigue, depression and anxiety ratings, autonomic symptoms and quality of life, with the use of questionnaires.
Subjects may be asked to stop taking some medications for up to 7 days; it will be decided on an individual basis and after considering each medication and its effect to the autonomic nervous system. If subjects are asked to discontinue the medication, they will ask them to keep a diary of symptoms and to contact the PI or staff by phone if any new symptom appears. If necessary, medications will be restarted.
Testing day 1:
In the morning during the posture test, 5 teaspoons of blood will be drawn while subject is lying down, and after sitting and or standing for 30 minutes to measure substances produced by the body in response to inflammation and oxidative stress and to determine hormones that regulate the blood pressure. Blood pressure and heart rate will be measured in these different positions. A total of 10 tablespoons will be drawn.
In the afternoon, more tests will be performed designed to determine how well the autonomic nervous system is working in regulating blood pressure and heart rate. Autonomic function test will be performed to see how the involuntary nervous system is working. For these tests, heart rate will be recorded using a continuous electrocardiographic trace, blood pressure using a cuff around one arm and/or finger and heart's pumping capacity (cardiac output) will be measured by analyzing the shift of fluids in the body (body impedance) and/or by analyzing the air that is breathe.
Participants will be tilted up on a tilt table for 10 minutes while recording their heart rate and blood pressure. The autonomic function tests include asking the participants to breathe deeply for two minutes and breathing rapidly for 30 seconds, maintaining a handgrip for 3 minutes, blowing against pressure for 15 seconds and placing one hand in ice water for 1 minute. All these tests are meant to stimulate the autonomic nervous system to produce changes in blood pressure and heart rate of short duration that reflect how well the involuntary nervous system is working.
Testing day 2:
In the morning, total blood volume will be measured by using iodinated I-131 tagged human serum albumin, a material with a very small amount of radioactive substance. The test involves drawing a blood sample before the I-131 is given, then giving the I-131 through a catheter in one vein, waiting 12 minutes before the second blood sample is drawn to check its concentration. Blood samples will also be drawn while subjects are lying down to measure for hormones, which control blood pressure and heart rate. Blood will drawn at several points during the study. The total amount of blood drawn during this study is approximately 3 teaspoons.
In the afternoon, exercise capacity test with estimation of maximal oxygen consumption (VO2 max) will be done. This test will be conducted on a stationary bicycle and the resistance will be gradually increased while the expired air is measured during exhaustive physical work. The test will last approximately 30 minutes. A mouthpiece with a one way re-breathing valve attached to a breathing tube will be used to collect air samples during the exercise test. Essentially, subjects will breathe room air through a mouthpiece, and then expire the air into a tube that connects to a machine (metabolic cart). This machine analyzes carbon dioxide and oxygen content, which allows us to calculate the amount of oxygen they are using under resting and exercise conditions.
The workload will be gradually increased on the bike by increasing the resistance. As the workload increases, oxygen consumption also increases. Throughout the test period exhaled air will be collected. When subjects can no longer continue, the test will be stopped. Blood pressure will be measured at the end of each resistance-stage. Heart rate data will be recorded continuously.
Before and after completing the exercise test, subjects will be required to complete a "warm-up" and "cool-down" session including stretching exercises.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Postural Tachycardia Syndrome
Keywords
Postural tachycardia syndrome, orthostatic intolerance, orthostatic tachycardia, POTS
7. Study Design
Primary Purpose
Screening
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
110 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
All participants
Arm Type
Other
Arm Description
All participants will be administered all procedures as described previously.
Interventions:
Autonomic Function Testing, Posture Study ,Measurement of Total Blood Volume ,Exercise Capacity Test
Intervention Type
Other
Intervention Name(s)
Autonomic Function Testing
Intervention Description
heart rate and blood pressure will be continuously monitored while participants undergo a variety of breathing techniques (deep breathing, rapid breathing, blowing against resistance) and during sustained handgrip and cold pressor (hand in ice water). All tests are meant to stimulate the autonomic nervous system to produce changes in blood pressure and heart rate of short duration that reflect how well the autonomic nervous system is functioning.
Also during autonomic function testing, cardiac output will be measured to analyze the shift of fluids in the body (body impedance) and / or by analyzing the air that is breathed.
Intervention Type
Other
Intervention Name(s)
Posture Study
Other Intervention Name(s)
Supine & standing blood pressure, heart rate & blood draws.
Intervention Description
Blood pressure, heart rate and blood samples (for catecholamines and hormones) will be measured & collected in the supine (lying) and upright position for each participant.
Intervention Type
Procedure
Intervention Name(s)
Measurement of Total Blood Volume
Other Intervention Name(s)
blood sample at baseline and at 12 minutes, I-131 is administered.
Intervention Description
Total blood volume is measured by using iodinated I-131 tagged human serum albumin.
Intervention Type
Other
Intervention Name(s)
Exercise Capacity Test
Other Intervention Name(s)
Masimal Oxygen Consumption Test
Intervention Description
Participants will ride on a stationary recumbent bicycle and the resistance will be gradually increased while expired air is measured.
Primary Outcome Measure Information:
Title
blood volume deviation (%) from individual predicted volumes
Description
Compare blood volume deviations using the 131-I-Albumin method. Deviations will be reported as a percentage deviation from an individual's predicted value. These values will be compared between POTS patients and healthy control groups.
Time Frame
2 days
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Age between 18-50 years old
Patients with suspected POTS and healthy volunteers
Sedentary healthy subjects of similar age and gender than patients will also be recruited.
Only female participants are eligible.
Able and willing to provide informed consent
Exclusion Criteria:
Smokers
Overt cause for postural tachycardia, i.e., acute dehydration
Significant cardiovascular, pulmonary, hepatic, or hematological disease by history or prior testing
Highly trained athletes
Subjects with somatization or severe anxiety symptoms will be excluded
Pregnant (positive pregnancy test) or breastfeeding
Hypertension defined as supine resting BP>145/95 mmHg off medications or needing antihypertensive medication
Other factors which in the investigator's opinion would prevent the participant from completing the protocol, including poor compliance during previous studies or an unpredictable schedule
Unable to give informed consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alfredo J Gamboa, MD
Organizational Affiliation
Vanderbilt University Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Vanderbilt University Medical Center
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37232
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Aldosterone & Sodium Regulation in Postural Tachycardia Syndrome - Screening
We'll reach out to this number within 24 hrs